Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

Background. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here we present 1-year efficacy and safety data of the SOLAR study.Ob...

Full description

Bibliographic Details
Main Authors: V. I. Mazurov, A. M. Lila, M. A. Korolev, A. M. Prystrom, A. V. Kundzer, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Krechikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva, A. A. Lutckii, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2023-03-01
Series:Научно-практическая ревматология
Subjects:
levilimab
monoclonal anti-il-6 receptor antibody
rheumatoid arthritis
Online Access:https://rsp.mediar-press.net/rsp/article/view/3284

Internet

https://rsp.mediar-press.net/rsp/article/view/3284

Similar Items